Hasbiotech has received “R&D and Innovation Award in medicine Sector”.

Ekonomize Magazine held the 8th Economy, Politics and Business World Award Ceremony which is organised traditionally every year. Our company Hasbiotech, carrying out sustainable works in medicine sector, has received “R&D and Innovation Award in medicine Sector”.

In the 8th ceremony held in Ankara Rixos Hotel and attended by prominent guests from political and business worlds, Deputy Development Minister, namely Adv. Yusuf Coşkun, and Kadir Gürbüz the Chief Editor of Economize Magazine presented “R&D and Innovation Award in medicine Sector” to our Director General Dr. Seyfullah Dağıstanlı.

Cuba’s Biotechnology Revolution

An interview with Mayda Mauri Pérez by Fortune Magazine.

Mayda Mauri Pérez is the director of Bio- CubaFarma, a Cuban institution that resembles Turkey’s Scientific and Technological Research Council (TÜBİTAK).

Mayda Mauri Pérez in an interview with Fortune magazine, Highlighting Cuba is drawing attention of the world pharmaceutical giants, Mayda Mauri Pérez states that 103 clinical researches of 51 drugs have been developed by the Cuban scientists between 1992 and 2008.

Pérez tells Cuban technological advance in pharmaceutical sector like this:

“Cuba has a powerful biotechnology industry with many generic drugs that are produced locally. Cuban Meningitis B Vaccine is exported to 15 countries and it plans to improve the efficiency of the vaccines used by developing new adjuvants (agent to help boost immune response). IV infection in Cuba is very low (0.1 percent). We are a country that has stopped the transition of HIV virus from mother to child. Every Cuban can reach the necessary treatment if needed. In contrast, cancer and cardiovascular diseases are the leading cause of death in Cuba. On the other hand, the clinic trials of six out of eight therapeutical vaccines continue under the Cuba Cancer Vaccine Program Molecular Immunology Center (CIM). Havana Immunoassay Centre (CIE) has thirty-three diagnosis tests that can diagnose, follow up and assess nineteen different diseases. I can say that Cuban children had the most vaccine in the world under broad protection provided by thirteen different vaccines.”

Expressing that Cuba has been making biotechnology infrastructure and “know-how” transfer to many countries and can cover their needs locally, Mayda Mauri Pérez states that Turkey is among these countries and adds that:

“We carry out original new molecule partnership over technology transfer to Turkey together with Hasbiotech. We started to build partnerships with other countries in the field of biotechnology in recent years. The clinical research of CimaVax and Racotumomab that are the Lung Cancer Vaccines which are produced in Cuba and available on the market will be conducted by Roswell Park, one of the prominent Institutes of America with a special agreement. Apart from that authorities have approved in 2014 that clinical trials of recombinant Epidermal Growth Factor that has been applied intralesional and used in the treatment of Diabetic Foot Ulcer will be conducted in U.S. We have signed strategic cooperation agreements with Russia and China in the field of biotechnology.”

Cuba has created a professional scientific infrastructure by starting training program since early 1980’s and followed up development strategy in biotechnology. It has included scientific institutes in different areas under the project of “Biological Front” that launched in 1981 specifically. Between 1980 and 1990, important scientific centers such as Genetic Engineering and Biotechnology Center (CIGB), Laboratory Animal Production Center (CENPALAB), National Biopreparation Center (BIOCEN) and Immunology Research Center and Molecular Immunology Center (CIM) had been established in Cuba. In addition, the existing institutes have been modeled to be added to the biotechnology industry.

Fortune Turkey Pharmaceuticals 2016 – Industry Explorations

Hasbiotech attends CPhIİstanbul fair.

Organized for the 3rd time in 2016, the CPhIİstanbul Pharmaceutical Exhibition will be held between June 1 and 3 at the Istanbul Congress Center, Harbiye. As Hasbiotech İlaç San. ve Tic. A.Ş., we will be present at our stand no: B151. We will be delighted to gather with you at our stand throughout the event.

Our Director General, Dr. Seyfullah Dağıstanlı, takes part in CPhI Istanbul 2015 as speaker

Dr. Seyfullah Dağıstanlı, our Director General and the Chairman of Pharmacovigilance Association gave a speech during the CPhI Istanbul Exposition that was held on 3-5 June 2015 in Istanbul Congress Center and attended by over 200 companies. Dr. Seyfullah Dağıstanlı indicated that CPhI is one of the most significant pharmaceutical organizations worldwide and remarked that the fact that the exposition is being organized in Turkey for the second time is an indicator of Turkey’s importance. In his speech titled “A 360º Tour in the Turkish Pharmaceutical Sector”, Dr. Seyfullah Dağıstanlı assessed the legal regulations concerning pharmaceuticals as well as current and past pharmaceutical policies in Turkey. In addition, during his interview, Dr. Dağıstanlı also attracted attention to “immunotherapy” that constitutes one of the most significant developments in the field of international healthcare and said that this method allowing treatment by way of the immune system suddenly become an instant success in parallel with the development of biotechnology. Dr. Seyfullah Dağıstanlı added, “It’s everyone’s dream, fantasy to develop a preventive vaccine against cancer. Recently, we had some promising developments regarding cancer therapy in the field of immune-oncology. To ensure that the cancer vaccine is useable by healthy people, it is not sufficient to administer several doses, we must make sure that it does not cause any damage for at least ten years. Thus, it is imperative to wait not from a medical but also from a legal viewpoint”.

In his speech titled “Healthcare and Biotechnology in Cuba” and delivered during the same organization, the Cuban Ambassador Alberto Gonzales Casals talked about the healthcare system in Cuba and the accomplishments in the fields of biotechnological product development and production. In his interview, Ambassador Casals indicated that the biotechnology journey that has begun in 90’s in Cuba is not continuing with 42 products patented worldwide. Alberto Gonzalez Casals also remarked that novel products yielded successful results in the treatment of many types of cancer.

For more detailed information about the article and organization:

“Nanobiotechnology Days 2015”, Sponsored by Hasbiotech, organized in İstanbul Kemerburgaz University.

Organized jointly by the Faculty of Engineering of Istanbul Kemerburgaz University, Nanotechnology Center of Sabancı University and Yıldız Techincal University, and sponsored by Hasbiotech, “Nanobiotechnology Days 2015” is held on 14-15 May 2015 in Istanbul Kemerburgaz University’s campus. Featuring speeches by experts from the United States of America, Britain and Argentina as well as 4 seminars, 1 workshop, 3 verbal and 14 poster presentations, the organization allowed investigators working in the related field to obtain a wide range of information and data about the development of novel drugs and treatment methods worldwide.

Two Renown Cuban Scientists came to Antalya for the 17th International Pharmaceutical Technology Symposium under the sponsorship of Hasbiotech

The level of participation was quite high at the international symposium held with the main theme “Pharmaceutical Nanotechnology: Innovations, Therapeutic Facilities and Technological Developments”. Cuban scientist Ernesto Lopes Mola, who attended the congress under the sponsorship of our company and made a presentation, provided information about the “Biotechnological Industry” of Cuba. Another Cuban scientist Jorge Berlanga-Acosta shared the developments related to the “Biotechnological Industry of Cuba” in detail. There were also 4 industry sessions on different issues at the 17th International Pharmaceutical Technology Symposium where the parties in relation to the issues gathered together.

The representatives of the Turkish Medicine and Medical Devices Agency (TİTCK), Social Security Institution (SGK), Scientific and Technological Research Council of Turkey (TÜBİTAK), European Union Commission, Association of Research-Based Pharmaceutical Companies (AİFD), Pharmaceutical Industry Association of Turkey (TİSD) and Pharmaceutical Manufacturers Association of Turkey (İEİS) as well as the senior executives of the domestic and foreign pharmaceutical companies including Hasbiotech and more than 60 local and foreign guest speakers attended the symposium.

Hasbiotech attended the 4th International Meeting on Pharmacy and Pharmaceutical Sciences

The current issues of the pharmaceutical sector were discussed at the 4th International Meeting on Pharmacy and Pharmaceutical Sciences held by the Faculty of Pharmacy of Marmara University at the Haydarpaşa Campus. Princess of Thailand Chulabhorn, a Professor of Pharmacology, attended the congress with her presentation titled “The Role of Medicinal Plants and Microorganisms in Drug Development”. 30 foreign and 50 local speakers, all of whom are competent in their own fields, attended the congress sponsored by our company.

The programme of the congress held between September 18 and 21 consisted of about 250 free announcements including 26 oral presentations, 1 workshop and 1 course. Toxicologist and General Manager of Hasbiotech Dr. Seyfullah Dağıstanlı, who made a presentation titled “Innovative Developments in the Turkish Pharmaceutical Industry” at the congress, said: “It was a congress where we shared important information in relation to the pharmaceutical industry together with the expert speakers coming from many different countries. This congress, at which we discussed the current situation of the industry, developments, innovations and future, is of great importance for all stakeholders.

The Cuban Revolution in Kayseri

Milliyet 23.12.2014 

While the relations between USA and Cuba are becoming normalised, the foundation of an investment is being laid between Turkey and Cuba which will have a worldwide impact. Entering into a partnership with the Cubans, Hasbiotech İlaç is preparing to produce the first Hepatitis C vaccine in Kayseri. The vaccine to be developed against the disease, whose treatment costs 18 billion dollars annually, will be exported from Kayseri to the entire world and an income of 1 billion dollars will be acquired. The foundation of the pharmaceutical plant will be laid in February which will be built in the Erciyes Technopark by Hasbiotech İlaç established through the partnership between Hasçelik, producing high quality and bright steel in the plants in Kocaeli and Konya, and Giraylar A.Ş., the only Turkish company in Cuba.

It will produce original medicines
While the relations between USA and Cuba are becoming normalised, the foundation of an investment is being laid between Turkey and Cuba which will have a worldwide impact. Entering into a partnership with the Cubans, Hasbiotech İlaç is preparing to produce the first Hepatitis C vaccine in Kayseri. The vaccine to be developed against the disease, whose treatment costs 18 billion dollars annually, will be exported from Kayseri to the entire world and an income of 1 billion dollars will be acquired. The foundation of the pharmaceutical plant will be laid in February which will be built in the Erciyes Technopark by Hasbiotech İlaç established through the partnership between Hasçelik, producing high quality and bright steel in the plants in Kocaeli and Konya, and Giraylar A.Ş., the only Turkish company in Cuba.
Seyfullah Dağıstanlı, General Manager of Hasbiotech, gave the following information about the investment that will cost for 10 million Euros at the first stage:
“When our investment group, Hasçelik, was searching for new areas of investment, the idea to produce equivalents of medicines that are expensive in Turkey came to the fore. We went to Cuba upon the recommendation of Ömer Giray, the owner of the only Turkish company in Cuba. The fact that Cuba has original medicines sounded very striking and we came to an agreement with the Cubans. In Turkey we will produce original drugs forming their molecules for the first time. Thus Kayseri will become a centre of biotechnology.”

Treatment will become cheaper
Dağıstanlı stated that they concentrated on the Hepatitis C vaccine in pursuit of original medicines:
“Until very recently, there was no medicine available that could treat Hepatitis C. There is brand new drug. The cost of the 3-month treatment with this drug rises up to 100 thousand liras. We will sell the Hepatitis C vaccine that we will produce in Kayseri for 100 dollars. There is no other pharmaceutical company that has produced this vaccine yet around the world. We will both prevent the spread of disease and save from high treatment costs in case of catching the illness thanks to the vaccine that is the protective treatment method.”

Technology from Cuba
Having stated that the technology required for vaccine production will be provided from Cuba, Dağıstanlı said that “We will conduct the clinical trials for the vaccine as the Turkish party.” Dağıstanlı continued as follows:
“As a result of the researches we conducted, we realized that Cuba was behind a number of drugs that we call bio-similar. We understood that there was Cuba in the background of the drugs produced by China, India and Iran. They are producing their own original drugs as well as generics. The investment in Kayseri also means that Cubans get into the EU market.”

Che was a doctor, too. 
One of the key figures of the Cuban Revolution, Ernesto ‘Che Guevara’, was a doctor, too. When Che, who is Argentine, was studying medicine at Buenos Aires University, he went on two tours in Latin America that will influence his world view. Meanwhile having witnessed widespread poverty, famine and diseases, Che graduated from the faculty of medicine in 1953. In 1959 he took over the government in Cuba under the leadership of Fidel Castro. Having supported the revolutionist movements around the world since 1965, Che was murdered in 1967 in Bolivia.

Hasbiotech and Recombio executed a partnership agreement.

Hasbiotech has executed a partnership agreement RECOMBIO, a Spanish company specializing in the immunotherapy of cancer and chronic viral diseases. Operating investigation centers in various countries, RECOMBIO has been reflecting its experience in the field of chronic viral diseases on its studies on immunotherapy options in cancer during the last decade. Setting out to treat cancer and chronic viral diseases throughout the world, RECOMBIO and Hasbiotech will be cooperating in the coming years in order to carry out new investigations in these fields and to make drugs accessible worldwide.

The Thrill of First Ever Domestic Molecule in Pharmaceutics

Sabah 04.03.2014 

The rapid growth trend experienced in recent years is encouraging Turkish companies to invest in areas under the monopoly of giants. Taking heart from this fact, Has Group of Kayseri decided to embark on the road to molecule production that is currently under the control of international companies. The investment is led by toxicology specialist Dr. Seyfullah Dağıstanlı. The work that has first been initiated 5 years ago within the structure of Hasbiotech will be yielding results upon the commissioning of the site investment. This 20-million Euro investment in Kayseri will lead the way for the discovery of a molecule for Hepatitis C therapy for which no vaccine is currently available worldwide. Dr. Dağıstanlı stated that they are well ahead of their competitors in terms of Hepatitis C molecule production and that they will be capable of producing the vaccine in near future.


Adding that the vaccine has a very high potential, Dr. Dağıstanlı stated: “The market for Hepatitis C vaccine has a magnitude of 35 million doses. We will be unrivalled in this field. Each dose will be sold for 100 dollars. When we multiply this by 5, we have a market of 175 million doses. We are very close to get a result”. Seyfullah Dağıstanlı remarked that they are also working on an anti-cancer drug.